"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
| Descriptor ID |
D018796
|
| MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
-
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov. 2025 Jan 13; 15(1):119-138.
-
A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors. J Transl Med. 2025 Jan 09; 23(1):37.
-
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know. Ann Emerg Med. 2025 Mar; 85(3):214-229.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25; 15(1):10213.
-
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
-
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10; 43(2):201-213.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov; 41(11):4125-4139.